Abstract
Influenza remains an important cause of morbidity and mortality, and incurs substantial economic costs (mainly due to hospitalisation) especially for the elderly aged 65 years or more, and among those with high-risk medical conditions. Influenza vaccination is the most effective control measure for both healthy populations and the chronically ill in whom complications of influenza cluster. Unfortunately, vaccination is less effective in the elderly and immunocompromised persons. Additional benefit may accrue from other health care interventions including antiviral therapy. Oseltamivir, a neuraminidase inhibitor, has become a drug of public health importance since it was included in influenza pandemic management plans. Many systematic reviews and meta-analyses of oseltamivir treatment and prophylaxis trials have been published. We provide a summary of the conclusions and review the various findings of economic analyses. Future randomised controlled trials should focus upon costly outcomes such as hospital admissions and should be conducted in populations at high risk of complications from influenza. Future economic analyses need to address variation in (1) willing-to-pay value, (2) annual attack rate of influenza, and (3) influenza vaccination effectiveness and uptake rates.
Keywords: Adolescents, adults, clinical impact, economic review, influenza, oseltamivir.
Infectious Disorders - Drug Targets
Title:Oseltamivir Use in Adolescents and Adults: Clinical and Economic Considerations
Volume: 13 Issue: 1
Author(s): J. Kevin Yin, Leon Heron, Glenn Salkeld, Harunor Rashid and Robert Booy
Affiliation:
Keywords: Adolescents, adults, clinical impact, economic review, influenza, oseltamivir.
Abstract: Influenza remains an important cause of morbidity and mortality, and incurs substantial economic costs (mainly due to hospitalisation) especially for the elderly aged 65 years or more, and among those with high-risk medical conditions. Influenza vaccination is the most effective control measure for both healthy populations and the chronically ill in whom complications of influenza cluster. Unfortunately, vaccination is less effective in the elderly and immunocompromised persons. Additional benefit may accrue from other health care interventions including antiviral therapy. Oseltamivir, a neuraminidase inhibitor, has become a drug of public health importance since it was included in influenza pandemic management plans. Many systematic reviews and meta-analyses of oseltamivir treatment and prophylaxis trials have been published. We provide a summary of the conclusions and review the various findings of economic analyses. Future randomised controlled trials should focus upon costly outcomes such as hospital admissions and should be conducted in populations at high risk of complications from influenza. Future economic analyses need to address variation in (1) willing-to-pay value, (2) annual attack rate of influenza, and (3) influenza vaccination effectiveness and uptake rates.
Export Options
About this article
Cite this article as:
Yin Kevin J., Heron Leon, Salkeld Glenn, Rashid Harunor and Booy Robert, Oseltamivir Use in Adolescents and Adults: Clinical and Economic Considerations, Infectious Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/18715265112129990008
DOI https://dx.doi.org/10.2174/18715265112129990008 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Searching the Staphylococcal Toxic Shock Syndrome Toxin -1 in Septic Children with negative Cultures: A Comparative Study in Tehran, Iran
Infectious Disorders - Drug Targets Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Reviews on Recent Clinical Trials Double Balloon Enteroscopy in Crohn’s Disease: Background and Current State of Play
Current Drug Targets Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Up Scaling Strategies to Improve the Industrial Production of Bacitracin at Largescale
Mini-Reviews in Medicinal Chemistry An Overview on the Pharmacokinetics of Quantum Dots
Current Drug Metabolism Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Imiquimod 5% Cream Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Efficacy of PD-1 or PD-L1 Inhibitors and Central Nervous System Metastases in Advanced Cancer: A Meta-Analysis
Current Cancer Drug Targets The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Gene Therapy for Allergic Diseases
Current Gene Therapy Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology New Therapeutic Targets and Drugs for the Treatment of Asthma
Mini-Reviews in Medicinal Chemistry Functional Chemokine Receptors in Allergic Diseases: Is CCR8 a Novel Therapeutic Target?
Mini-Reviews in Medicinal Chemistry A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Anatomical and Histological Factors Affecting Intranasal Drug and Vaccine Delivery
Current Drug Delivery Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets